Ipamorelin vs Sermorelin vs CJC-1295: How These Growth Hormone Peptides Compare

Ipamorelin, sermorelin, and CJC-1295 all raise growth hormone by acting on the pituitary gland, but they are not interchangeable. Ipamorelin is a selective ghrelin-receptor agonist, sermorelin is a short-acting GHRH analog, and CJC-1295 is a longer-lasting GHRH analog sold both with and without a drug affinity complex (DAC). The differences that matter most in practice are half-life, dosing frequency, side-effect profile, and legal status in the United States.

None of the three is FDA-approved as a general-purpose therapy for healthy adults who simply want higher growth hormone levels. Sermorelin once held FDA approval as a pediatric diagnostic under the brand name Geref, but that product is no longer marketed. CJC-1295 and ipamorelin have never been approved for human use and are sold almost entirely as research chemicals.

How Each Peptide Works

All three compounds act on the same hormonal chain running from the hypothalamus to the pituitary to the liver. Where they diverge is the receptor they bind and how long they stay active in the bloodstream.

Ipamorelin

Ipamorelin is a synthetic pentapeptide that mimics ghrelin at the growth hormone secretagogue receptor, known as GHSR-1a. Early research suggests it triggers a growth hormone pulse with far less effect on cortisol, prolactin, and appetite than older secretagogues such as GHRP-6. Its half-life is roughly two hours.

Sermorelin

Sermorelin is the first 29 amino acids of growth hormone-releasing hormone, which is why it is often written as GRF 1-29. It binds GHRH receptors on the pituitary and produces a pulse that resembles the body's natural nighttime growth hormone surge. Its half-life is extremely short, on the order of 10 to 20 minutes.

CJC-1295

CJC-1295 is a modified GHRH analog. The DAC version binds to albumin in the blood, stretching its half-life to roughly six to eight days. CJC-1295 without DAC, frequently labeled mod GRF 1-29, clears in about 30 minutes and behaves much more like sermorelin.

Ipamorelin vs Sermorelin vs CJC-1295 at a Glance

Peptide	Receptor target	Approx. half-life	Commonly reported dosing	FDA status
Ipamorelin	GHSR-1a (ghrelin receptor)	About 2 hours	100-300 mcg, 2-3 times daily	Not approved for human use
Sermorelin	GHRH receptor	10-20 minutes	100-300 mcg at bedtime	Formerly approved as a diagnostic; brand no longer marketed
CJC-1295 with DAC	GHRH receptor	6-8 days	1-2 mg weekly	Not approved for human use
CJC-1295 without DAC	GHRH receptor	About 30 minutes	100 mcg, 2-3 times daily	Not approved for human use

The dosing figures above come from published research protocols and clinic materials, not from FDA-approved labeling. Anyone researching sermorelin vs cjc-1295 no dac ipamorelin should keep that distinction in mind, because the modified and unmodified versions are frequently confused in online discussions.

Why Half-Life and Stacking Choices Matter

Growth hormone is released in pulses, mostly during deep sleep. How closely a peptide imitates that pattern depends largely on how fast it clears the body.

• Sermorelin produces a brief, natural-looking pulse, which is why bedtime dosing is standard.
• CJC-1295 without DAC behaves similarly and is often paired with a ghrelin-receptor peptide for a stronger combined signal.
• CJC-1295 with DAC keeps growth hormone and IGF-1 elevated for days rather than minutes. Some clinicians argue that steady elevation is not the same as physiologic pulsatility, and that debate remains unresolved.
• Ipamorelin sits in the middle, which makes it convenient to stack with a GHRH analog.

Combination protocols are common. Someone weighing cjc-1295 vs ipamorelin is usually comparing two different mechanisms rather than two versions of the same drug, and many protocols use both together. The recurring cjc-1295 ipamorelin vs hgh debate comes down to whether you want the pituitary to release its own growth hormone or to inject recombinant growth hormone directly.

AOD-9604 is a separate case. In any aod 9604 vs cjc-1295 ipamorelin comparison, note that AOD-9604 targets fat metabolism rather than growth hormone release, so it belongs to a different category of compound altogether.

Side Effects and Safety Considerations

Any agent that raises growth hormone or IGF-1 can cause water retention, joint aching, tingling in the hands, headache, and irritation at the injection site. Those effects generally track with dose and with how high IGF-1 climbs.

Longer-term elevation of growth hormone and IGF-1 carries more serious theoretical risks, including insulin resistance, soft-tissue swelling, and changes associated with acromegaly. People with active cancer, pregnancy, or uncontrolled diabetes are usually advised to avoid growth-hormone-stimulating peptides. Human safety data for ipamorelin and CJC-1295 are limited and come mostly from small, short studies.

These peptides are not proven anti-aging treatments, and the evidence that they meaningfully change body composition or longevity in healthy adults is thin. Anyone considering them should speak with a licensed healthcare professional rather than following forum protocols.

Legal and Regulatory Status in the United States

Sermorelin's original brand product is no longer marketed, and the FDA has raised questions about the safety evidence supporting compounded versions. Ipamorelin and CJC-1295 are sold almost exclusively as research chemicals labeled not for human consumption, which is a legal workaround rather than an approval.

A cjc-1295 ipamorelin vs tesamorelin comparison highlights the gap clearly. Tesamorelin, sold as Egrifta, is the only GHRH analog in this family with current FDA approval, and it is approved only for HIV-associated lipodystrophy, not for general weight loss or anti-aging use.

Importing these peptides for personal use generally violates federal law, and shipments are subject to seizure by customs officials.

The Bottom Line

Sermorelin offers the shortest, most pulse-like growth hormone release. CJC-1295 with DAC offers the longest. Ipamorelin is the most receptor-selective of the three and is often combined with a GHRH analog rather than used alone.

None of them is a remedy for low energy, stubborn body fat, or aging. Treat the dosing tables you find online as research context, verify where the information comes from, and get medical guidance before putting anything into your body.

RELATED PEPTIDE TOPICIpamorelin peptide

COMMON QUESTIONS

Frequently Asked Questions

Is ipamorelin stronger than CJC-1295?

They work through different receptors, so stronger is not really the right comparison. Ipamorelin stimulates the ghrelin receptor and creates a shorter pulse of growth hormone, while CJC-1295 with DAC keeps growth hormone and IGF-1 elevated for several days. Many research protocols combine the two rather than choosing between them.

Is sermorelin safer than CJC-1295?

Sermorelin has the longest safety track record of the three because it was studied and briefly marketed as a prescription diagnostic product. Its short half-life also means it clears the body quickly if side effects appear. CJC-1295 with DAC stays active for days, so any adverse effect would linger longer, and long-term human data for both peptides are limited.

Can you legally buy ipamorelin or CJC-1295 in the US?

No. Neither peptide is FDA-approved for human use, and products sold online are labeled for research purposes only. Importing them for personal use generally violates federal law and shipments can be seized by customs. Compounded versions of these peptides require a prescription from a licensed clinician, and state rules vary.